These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 5775069)

  • 41. [Availability of active substances in and on the skin. Comparative study of the liberation and penetration of various cyproterone and cyproterone acetate ointments].
    Kotwas J; Schaefer H; Zesch A
    Arzneimittelforschung; 1979; 29(3):562-8. PubMed ID: 582747
    [No Abstract]   [Full Text] [Related]  

  • 42. Percutaneous absorption. Influence of temperature and hydration.
    Stoughton RB
    Arch Environ Health; 1965 Oct; 11(4):551-4. PubMed ID: 5837406
    [No Abstract]   [Full Text] [Related]  

  • 43. Influence of ointment formulation on skin erythema induced by nicotinate esters.
    Realdon N; Ragazzi E; Dal Zotto M; Ragazzi E
    Pharmazie; 1995 Sep; 50(9):603-6. PubMed ID: 7480096
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The cutaneous reactions to kallikrein, prostaglandin and thurfyl nicotinate in chronic urticaria and the effect of polyphloretin phosphate.
    Thune P; Ryan TJ; Powell SM; Ellis JR
    Acta Derm Venereol; 1976; 56(3):217-21. PubMed ID: 59506
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Factors influencing the penetration of corticosteroids through the epidermis.
    Polano MK; Ponec M; Smeenk G; Hendrikse JC
    Adv Biol Skin; 1972; 12():325-38. PubMed ID: 4579199
    [No Abstract]   [Full Text] [Related]  

  • 46. Kinetics of blood flow after topical application of benzyl nicotinate on different anatomic sites.
    Jacobi U; Kaiser M; Sterry W; Lademann J
    Arch Dermatol Res; 2006 Nov; 298(6):291-300. PubMed ID: 16967307
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Percutaneous absorption of nicotinic acid and ethyl nicotinate in human skin.
    CRONIN E; STOUGHTON RB
    Nature; 1962 Sep; 195():1103-4. PubMed ID: 13882335
    [No Abstract]   [Full Text] [Related]  

  • 48. On the absorption, excretion and metabolism of pentaerythritoltetranicotinate.
    Harthon L; Sigroth K
    Arzneimittelforschung; 1974 Oct; 24(10):1688-92. PubMed ID: 4373013
    [No Abstract]   [Full Text] [Related]  

  • 49. Methyl nicotinate-induced vasodilation in generalized social phobia.
    Katzman M; Cornacchi S; Coonerty-Femiano A; Hughes B; Vermani M; Struzik L; Ross BM
    Neuropsychopharmacology; 2003 Oct; 28(10):1846-51. PubMed ID: 12888773
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mechanism of action of accelerants. The effect of cutaneously-applied penetration accelerants on the skin circulation of the rat.
    Creasey NH; Allenby AC; Schock C
    Br J Dermatol; 1971 Oct; 85(4):368-80. PubMed ID: 5125640
    [No Abstract]   [Full Text] [Related]  

  • 51. Plasma levels of nicotinic acid compounds in niceritrol-treated rabbits.
    Brattsand R; Harthon L
    Acta Pharmacol Toxicol (Copenh); 1975 Mar; 36(3):203-14. PubMed ID: 124527
    [No Abstract]   [Full Text] [Related]  

  • 52. Enhanced percutaneous absorption of a novel topical cyclosporin A formulation and assessment of its immunosuppressive activity.
    Duncan JI; Payne SN; Winfield AJ; Ormerod AD; Thomson AW
    Br J Dermatol; 1990 Nov; 123(5):631-40. PubMed ID: 2147390
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The microvascular response in the skin to topical application of methyl nicotinate: Effect of concentration and variation between skin sites.
    Elawa S; Mirdell R; Tesselaar E; Farnebo S
    Microvasc Res; 2019 Jul; 124():54-60. PubMed ID: 30877017
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Quantitative evaluation of drug-induced erythema by using a tristimulus colour analyzer: experimental design and data analysis.
    Chan SY; Li Wan Po A
    Skin Pharmacol; 1993; 6(4):298-312. PubMed ID: 8198816
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In-vitro and in-vivo evaluation of oligoethylene esters as dermal prodrugs of 18beta-glycyrrhetic acid.
    Puglia C; Ostacolo C; Sacchi A; Laneri S; Bonina F
    J Pharm Pharmacol; 2006 Mar; 58(3):311-9. PubMed ID: 16536897
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A comparative study of the absorption of xanthinol nicotinate from slow-release and plain tablets in man.
    Sharma PL; Garg SK; Sikka SC
    Int J Clin Pharmacol; 1973 Jul; 7(4):299-302. PubMed ID: 4146912
    [No Abstract]   [Full Text] [Related]  

  • 57. Enhancement of bioavailability by lowering of fat content in topical formulations.
    Wirén K; Frithiof H; Sjöqvist C; Lodén M
    Br J Dermatol; 2009 Mar; 160(3):552-6. PubMed ID: 19120336
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [On interactions of drugs on and in the skin/comparative studies on the mutual influences of ethyleneglycol-monosalicylate and benzylnicotinate (author's transl)].
    Zesch A; Schaefer H
    Derm Beruf Umwelt; 1981; 29(6):161-7. PubMed ID: 7338200
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The cellular inflammatory response in nicotinate skin reactions.
    English JS; Winkelmann RK; Louback JB; Greaves MW; MacDonald DM
    Br J Dermatol; 1987 Mar; 116(3):341-9. PubMed ID: 3567073
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Preparation and in vivo control of the sustained release of a delayed-action preparation: 7-(2-hydroxy-3-((2-hydroxyethyl)-methylamino)-propyl)-thiophylline nicotinate].
    Belligno A; Zanotti A; Girlando M; Ottaviano G
    Boll Chim Farm; 1972 Aug; 111(8):500-6. PubMed ID: 4647090
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.